Loading...
SCYNEXIS, Inc.
SCYX•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.73
$0.003(0.34%)
SCYNEXIS, Inc. (SCYX) Financial Performance & Income Statement Overview
Review SCYNEXIS, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-97.33%
↓ 97.33%
Operating Income Growth
-151.08%
↓ 151.08%
Net Income Growth
-131.75%
↓ 131.75%
Operating Cash Flow Growth
-139.91%
↓ 139.91%
Operating Margin
-1526.34%
↓ 1526.34%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-1141.59%
↓ 1141.59%
ROE
-48.26%
↓ 48.26%
ROIC
-61.43%
↓ 61.43%
SCYNEXIS, Inc. (SCYX) Income Statement & Financial Overview
Review SCYNEXIS, Inc.'s (SCYX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $977000.00 | $660000.00 | $736000.00 | $1.37M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $977000.00 | $660000.00 | $736000.00 | $1.37M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $4.31M | $8.07M | $6.81M | $7.21M |
| SG&A Expenses | $4.72M | $2.91M | $3.17M | $3.67M |
| Operating Expenses | $9.03M | $10.98M | $9.97M | $10.88M |
| Total Costs & Expenses | $9.03M | $10.98M | $9.97M | $10.88M |
| Interest Income | $869000.00 | $1.02M | $1.13M | $1.28M |
| Interest Expense | $675000.00 | $213000.00 | $197000.00 | $205000.00 |
| Depreciation & Amortization | $464000.00 | $7.33M | $145000.00 | $145000.00 |
| EBITDA | -$3.73M | -$2.99M | -$13.84M | -$9.36M |
| EBITDA Ratio | -$3.82 | -$4.53 | -$18.80 | -$6.82 |
| Operating Income | -$8.05M | -$10.32M | -$9.24M | -$9.51M |
| Operating Income Ratio | -$8.24 | -$15.64 | -$12.55 | -$6.92 |
| Other Income/Expenses (Net) | $3.64M | $7.12M | -$5.22M | $10.45M |
| Income Before Tax | -$4.41M | -$3.20M | -$14.46M | $942000.00 |
| Income Before Tax Ratio | -$4.51 | -$4.85 | -$19.64 | $0.69 |
| Income Tax Expense | $23000.00 | -$395000.00 | $8000.00 | $531000.00 |
| Net Income | -$4.43M | -$2.81M | -$14.46M | $411000.00 |
| Net Income Ratio | -$4.54 | -$4.25 | -$19.64 | $0.30 |
| EPS | -$0.09 | -$0.06 | -$0.30 | $0.009 |
| Diluted EPS | -$0.09 | -$0.06 | -$0.30 | $0.009 |
| Weighted Avg Shares Outstanding | $37.97M | $48.62M | $48.51M | $48.25M |
| Weighted Avg Shares Outstanding (Diluted) | $37.97M | $48.62M | $48.51M | $48.57M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan